Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6489362
Carnitine supplemented diet to prevent or alleviate ascites in broiler type poultry
expired -
US 6489163
Ribozyme mediated inactivation of the androgen receptor
expired -
US 6485722
Method for selective engraftment of drug-resistant hematopoietic stem cells
expired -
US 6486166
Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections
expired -
US 6486125
Synthesis of soluble &bgr;-sheet forming peptides
expired -
US 6485928
Use of granulysin as an antimicrobial agent
expired -
US 6482411
Methods of reducing bone loss with CD40 ligand
expired -
US 6482795
Tumor suppressor designated TS10q23.3
expired -
US 6482803
Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
expired -
US 6482435
Temperature sensitive gel for sustained delivery of protein drugs
expired -
US 6479662
Antitumor dibenzofluorene derivatives
expired -
US 6479546
Allosteric inhibitors of lipoxygenase
expired -
US 6475508
Methods and pharmaceutical compositions for the closure of retinal breaks
expired -
US 6476236
Synthesis of 2-cyanoaziridine-1-carboxamide
expired -
US 6476037
L-arginine and phosphodiesterase (PDE) inhibitor synergism
expired -
US 6475985
Nucleosides with antiviral and anticancer activity
expired -
US 6475789
Human telomerase catalytic subunit: diagnostic and therapeutic methods
expired -
US 6475724
Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
expired -
US 6475489
Synthesis of human virus antigens by yeast
expired -
US 6471968
Multifunctional nanodevice platform
expired -
US 6471967
Recombinant intracellular pathogen vaccines and methods for use
expired -
US 6472197
GRB2 associating polypeptides and nucleic acids encoding therefor
expired -
US 6472369
Anticancer compounds and methods
expired -
US 6469027
N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
expired -
US 6470220
Diagnosis and treatment of cancers using in vivo magnetic domains
expired -
US 6469184
Total synthesis of antitumor acylfulvenes
expired -
US 6468798
Expression of cloned genes in the lung by aerosol and liposome-based delivery
expired -
US 6465614
High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
expired -
US 6465612
Synthetic peptides, conjugation reagents and methods
expired -
US 6465001
Treating medical conditions by polymerizing macromers to form polymeric materials
expired -
US 6465627
DAX-1 protein, methods for production and use thereof
expired -
US 6461806
Methods for measuring cellular proliferation and destruction rates in vitro and in vivo
expired -
US 6461640
Local delivery of fibrinolysis enhancing agents
expired -
US 6461613
Methods and compositions for the selective regulation of chorionic prostanoids
expired -
US 6458937
Glycoconjugates and methods
expired -
US 6458766
Halovir, an antiviral marine natural product, and derivatives thereof
expired -
US 6454759
Microfabricated injectable drug delivery system
expired -
US 6455541
Suppression, by 5-lipoxygenase inhibitors, of bone resorption
expired -
US 6455589
Primary N-hydroxylamines
expired -
US 6455493
Methods for using heat shock proteins
expired -
US 6455063
Propionibacterium P-63 for use in direct fed microbials for animal feeds
expired -
US 6455027
Methods and kits for identifying ductal orifices in a nipple
expired -
US 6451306
Methods for therapy of neurodegenerative disease of the brain
expired -
US 6451312
VEGF-gelonin for targeting the vasculature of solid tumors
expired -
US 6451596
Helper adenovirus vectors
expired -
US 6451759
Noncleavable Fas ligand
expired -
US 6451765
Methods for treating breast cancer using Mammastatin
expired -
US 6451594
Recombinant adenovirus for tissue specific expression in heart
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory